218800-01-2

Upstream product

• 218800-28-3 1-bromomethyl-2-chloro-5-methoxy-3-methyl-benzene 
• 117850-13-2 N-(1,1-dimethylethyl)-3,5-dimethyl-2-pyridine carboxamide 
• 6981-15-3 4-chloro-3,5-dimethylanisole 
• 874-63-5 3,5-dimethylmethoxybenzene 

Downstream Products

• 218800-02-3 3-[2-(2-chloro-5-methoxy-3-methyl-phenyl)-ethyl]-5-methyl-pyridine-2-carbonitrile 
• 218800-04-5 7-chloro-10-methoxy-3,8-dimethyl-11-(1-methyl-piperidin-4-yl)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ol 
• 218800-05-6 4-(7-chloro-11-hydroxy-10-methoxy-3,8-dimethyl-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-piperidine-1-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Analogs of 4-(3-bromo-8-methyl-10-methoxy-6,11-dihydro-5H- benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-(4-pyridinylacetyl)piperidine N- oxide as inhibitors of farnesyl protein transferase

A series of 3-substituted analogs 3 of 4-(3-bromo-8-methyl-10-methoxy- 6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2b]pyridin-11-yl)-1-(4- pyridinylacetyl)piperidine N-oxide 2 was prepared and evaluated as FPT inhibitors. The objective of this study was to identify other substituents at C3 in this series of FPT inhibitors that would have the FPT potency enhancement similar to that found for a C3 bromo substituent. The 3-methyl analog 17b was found to be tenfold less active than 2, and other C3 substituents having more steric bulk were found to cause a further reduction in activity.